Dec 14, 2017
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...
356
Dec 10, 2017
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
IKEMA Isa-Kd Vs Kd Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In...
471
Dec 8, 2017
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...
82
Dec 7, 2017
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...
365
Dec 7, 2017
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...
158
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
191
Dec 16, 2016
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...
96
Dec 13, 2016
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
ICARIA Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory...
303
Dec 8, 2016
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
ELOQUENT-3 trial NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without...
307
Dec 8, 2016
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...
231
Dec 10, 2015
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...
173
Dec 4, 2015
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...
271
Dec 19, 2014
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
MMY3003 (POLLUX) Study NCT02076009: Phase 3: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and...
386
Dec 13, 2014
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
TOURMALINE-MM3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous...
368
Dec 12, 2014
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
ALCYONE trial NCT02195479: Phase 3: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared...
308
Dec 12, 2014
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...
491
Dec 12, 2014
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
CENTAURUS A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma The purpose of this study...
170
Dec 11, 2014
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
The CASTOR Trial Dara Vd DVd NCT02136134: Phase 3: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants...
503
Dec 9, 2014
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE
TOURMALINE-MM4 Trial NCT02312258: Phase 3: A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple...
65